Notice Number: NOT-DA-05-021

Key Dates
Release Date: March 7, 2005

RFP Available: N01DA-5-8853

Synopsis No. N01DA-5-8853
National Institute on Drug Abuse
6101 Executive Blvd., Room 260, MSC 8402
Bethesda, MD 20892-9551

The National Institute on Drug Abuse plans to solicit proposals from qualified organizations having in-house capabilities and experience to perform testing of compounds in the rat self-administration test for assessment as potential pharmacotherapies for drugs of abuse including stimulants and hallucinogens. In addition, the capability and experience to assess compounds for the ability to maintain self-administration behavior will be required. Proprietary compounds will be evaluated using established protocols, and the resulting data will be utilized by the Treatment Discovery Programs of the NIDA Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMC). Data generated by these activities will be utilized by NIDA in the selection of compounds for additional preclinical efficacy and safety evaluation. In addition, data generated under this agreement will sometimes be provided by NIDA to the U.S. Drug Enforcement Administration (DEA) to support scheduling recommendations for new street drugs .

In order to handle substances under the Controlled Substances Act of 1970, it is mandatory that interested entities possess a DEA Research Registration for Schedules II to V and demonstrate the capability to obtain a DEA registration for Schedule I controlled substances. All offerors must comply with NIH guidelines on the care and use of laboratory animals. We anticipate the award of one cost reimbursement contract for a base period of five years. The contract will include additional quantity options. RFP No. N01DA-5-8853 will be available electronically on or about March 18, 2005 . You will access the RFP through the FedBizOpps (URL: http://www.fedbizopps.gov) or through the NIDA website: (URL: http://www.nida.nih.gov/RFP/RFPList.html). Please note that NIDA uses a streamlined RFP format which includes only the Work Statement, Deliverables, Reporting Requirements, Special Requirements, Mandatory Qualifications, Technical Evaluation Criteria, and other necessary Proposal Preparation Instructions. All information required for the submission of a proposal is contained in or accessible through the streamlined RFP package. Response to the RFP will be due on or about May 6, 2005. NIDA will consider proposals submitted by any responsible offeror. This advertisement does not commit the Government to award a contract. See Note 26.

Inquiries

Point of Contact:

Pedro M. Godinez, Contracting Specialist
National Institute on Drug Abuse, NIH
Contracts Management Branch, OPRM
6101 Executive Blvd., Room 260, MSC 8402
Bethesda, Maryland 20892-8402
E-mail: pg186o@nih.gov
Telephone: (301) 443-6677
Fax: (301) 443-7595

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.